Search

Your search keyword '"Tibaldi, C."' showing total 388 results
Start Over Author "Tibaldi, C."
388 results on '"Tibaldi, C."'

101. An investigation on wind turbine resonant vibrations.

Author

Tibaldi, C., Kim, T., Larsen, T. J., Rasmussen, F., Rocca Serra, R. de, and Sanz, F.

Subjects
RESONANT vibration, WIND turbine aerodynamics, AEROELASTICITY, WIND power, TURBULENCE, TIME-domain analysis
Abstract

Wind turbine resonant vibrations are investigated based on aeroelastic simulations both in frequency and time domain. The investigation focuses on three different aspects: the need of a precise modeling when a wind turbine is operating close to resonant conditions; the importance of estimating wind turbine loads also at low turbulence intensity wind conditions to identify the presence of resonances; and the wind turbine response because of external excitations. In the first analysis, three different wind turbine models are analysed with respect to the frequency and damping of the aeroelastic modes. Fatigue loads on the same models are then investigated with two different turbulence intensities to analyse the wind turbine response. In the second analysis, a wind turbine model is excited with an external force. This analysis helps in identifying the modes that might be excited, and therefore, the frequencies at which minimal excitation should be present during operations. The study shows that significant edgewise blade vibrations can occur on modern wind turbines even if the aeroelastic damping of the edgewise modes is positive. When operating close to resonant conditions, small differences in the modeling can have a large influence on the vibration level. The edgewise vibrations are less visible in high turbulent conditions. Using simulations with low-level turbulence intensity will ease this identification and could avoid a redesign. Furthermore, depending on the external excitation, different aeroelastic modes can be excited. The investigation is performed using aeroelastic models corresponding to a 1.5 MW class wind turbine with slight variations in blade properties. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

102. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer

Author

Conte, P. F., Michelotti, A., Baldini, E., Salvadori, B., Alessandra Gennari, Da Prato, M., Tibaldi, C., Salzano, E., and Gentile, A.

Subjects
Adult, Infusions, Neutropenia, Fever, Filgrastim, Paclitaxel, Left, Antineoplastic Agents, chemically induced/drug therapy, Breast Neoplasms, administration /&/ dosage/adverse effects, Ventricular Function, Left, Injections, administration /&/ dosage/therapeutic use, Cohort Studies, Antibiotics, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, Adult, Aged, Antibiotics, Antineoplastic, administration /&/ dosage/adverse effects, Antineoplastic Agents, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage/adverse effects/therapeutic use, Breast Neoplasms, drug therapy, Chemotherapy, Adjuvant, Cohort Studies, Drug Tolerance, Epirubicin, administration /&/ dosage/adverse effects, Feasibility Studies, Female, Fever, chemically induced, Granulocyte Colony-Stimulating Factor, administration /&/ dosage/therapeutic use, Heart Failure, chemically induced, Heart, drug effects, Humans, Infusions, Intravenous, Injections, Intravenous, Middle Aged, Neutropenia, chemically induced/drug therapy, Paclitaxel, administration /&/ dosage/adverse effects, Peripheral Nervous System Diseases, chemically induced, Recombinant Proteins, Remission Induction, Stroke Volume, drug effects, Ventricular Function, drug effects, Chemotherapy, Ventricular Function, Humans, Infusions, Intravenous, Adjuvant, Aged, Epirubicin, Heart Failure, administration /&/ dosage/adverse effects/therapeutic use, Antibiotics, Antineoplastic, Remission Induction, Peripheral Nervous System Diseases, Heart, Stroke Volume, Drug Tolerance, Middle Aged, Antineoplastic Agents, Phytogenic, Recombinant Proteins, drug therapy, Chemotherapy, Adjuvant, Injections, Intravenous, chemically induced, Feasibility Studies, Female, Intravenous
Abstract

We performed a dose escalation study to evaluate the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given over 3 hours plus bolus epirubicin 90 mg/m2. The starting dose of paclitaxel, 135 mg/m2, was escalated by 20-mg/m2 increments in cohorts of three to six patients. Courses were repeated every 3 weeks. Filgrastim (5 micrograms/kg/d) was administered to shorten the duration of grade 4 neutropenia lasting longer than 72 hours. Twenty-nine patients have been treated, 86% of whom had failed adjuvant chemotherapy (with anthracyclines in 14 cases). One hundred forty-eight courses have been administered, and the paclitaxel dose has been escalated to 225 mg/m2 without reaching the maximum tolerated dose. The most frequent dose-related toxicity has been grade 4 neutropenia, which occurred in 59% of courses. The median duration of grade 4 neutropenia was 4 days, which was shortened with filgrastim only in patients treated with paclitaxel 225 mg/m2. Eleven episodes of febrile neutropenia (7% of courses) have been observed. Nonhematologic toxicities were mild or moderate: grade 1 or 2 peripheral neuropathy was reported by 41% and 10% of patients, respectively. The cardiac toxicities of this regimen were surprisingly low: median left ventricular ejection fraction was 57% at study entry and 56% after six courses. Only two patients showed a decrease of left ventricular ejection fraction below 50% after six courses, and no signs of anthracycline-induced congestive heart failure were noted. The activity of this novel combination is encouraging: the overall response rate is 80%, with 16% complete responses. We have demonstrated that the combination of epirubicin plus paclitaxel given over 3 hours is feasible with acceptable toxicities, does not appear to be associated with clinically relevant cardiotoxicity, and is active in a population of patients who have failed adjuvant chemotherapy.

Published
1996

103. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer

Author

PIERFRANCO CONTE, Michelotti, A., Baldini, E., Tibaldi, C., Daprato, M., Salvadori, B., Giannessi, P. G., Gentile, A., Biadi, O., and Mariani, M.

Subjects
Adult, Antibiotics, Antineoplastic, Neutropenia, Paclitaxel, Antineoplastic Agents, Breast Neoplasms, Middle Aged, administration /&/ dosage/adverse effects, drug therapy/pathology, Antineoplastic, Antineoplastic Agents, Phytogenic, Adult, Aged, Antibiotics, administration /&/ dosage/adverse effects, Antineoplastic Agents, Phytogenic, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage/adverse effects, Breast Neoplasms, drug therapy/pathology, Epirubicin, administration /&/ dosage/adverse effects, Female, Humans, Middle Aged, Neutropenia, chemically induced, Paclitaxel, administration /&/ dosage/adverse effects, Ventricular Function, drug effects, Antibiotics, Antineoplastic Combined Chemotherapy Protocols, chemically induced, Humans, Ventricular Function, Female, Aged, Epirubicin
Abstract

We performed a dose-escalation study to evaluate the maximum tolerated dose (MTD) of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus a fixed dose of epirubicin. Epirubicin was administered as a 90 mg/m2 bolus immediately followed by a 3-hour infusion of paclitaxel starting at 135 mg/m2 and escalating by 20mg/m2 for each triplet of patients as long as no dose-limiting toxicity had occurred; courses were repeated every 3 weeks. The MTD was defined as that at which any of the following toxicities occurred in at least two of six patients: absolute neutrophil count less than 500/microliter for more that 7 days or less than 100/microliter for more than 3 days; any episode of febrile neutropenia requiring intravenous antibiotics and hospitalization; grade 4 thrombocytopenia requiring platelet transfusion; failure to recover absolute neutrophil count toor = 1,500/microliter and/or platelets toor = 100,000/microliter by day 28; and any gradeor = 3 nonhematologic toxicity. Two MTDs were defined: the first without granulocyte colony-stimulating factor (MTD 1) and the second with granulocyte colony-stimulating factor given either to accelerate recovery of grade 4 neutropenia lasting more than 72 hours or immediately in case of febrile neutropenia (MTD 2); granulocyte colony-stimulating factor was never used prophylactically. To date, 22 patients have been entered into the study; the median patient age was 55 years (age range, 30 to 66 years). Nineteen (86%) patients had received adjuvant chemotherapy that included anthracyclines in 12 cases (55%). The viscera were the dominant sites of disease in 55% of patients. Median baseline ventricular ejection fraction was 58% (range, 53% to 67%). Short-lasting grade 4 neutropenia occurred in 61% of courses; however, only four episodes of febrile neutropenia were recorded. Grade 4 thrombocytopenia was reported in 8% and grade 3 anemia in 3% of courses; four patients experienced peripheral neuropathy (three patients grade 1, one patient grade 2); complete alopecia was universal. The cardiac effects of the combination were surprisingly low: median ejection fraction at study entry was 58%, and after a cumulative dose 1,080 mg/m2 it was 56%. Three complete responses and 12 partial responses have been documented for an overall response rate of 83.3% (95% confidence interval, 58% to 96%). In conclusion, neutropenia is the most frequent toxicity of this novel combination. However, the MTD has not yet been reached. The combination of epirubicin plus paclitaxel is highly active, and no signs of cumulative myocardiopathy have been observed.

Published
1996

107. A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer

Author

Tibaldi, C., Baldini, E., Ricci, S., and PIERFRANCO CONTE

Subjects
Male, Lung Neoplasms, Neutropenia, Pilot Projects, drug therapy/pathology, Vinblastine, Drug Administration Schedule, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, administration /&/ dosage/adverse effects/analogs /&/ derivatives, Humans, Ifosfamide, Non-Small-Cell Lung, administration /&/ dosage, Aged, Neoplasm Staging, Carcinoma, Vinorelbine, Middle Aged, therapeutic use, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, drug therapy/pathology, Cisplatin, administration /&/ dosage, Drug Administration Schedule, Feasibility Studies, Female, Granulocyte Colony-Stimulating Factor, administration /&/ dosage, Humans, Ifosfamide, administration /&/ dosage, Lung Neoplasms, drug therapy/pathology, Male, Middle Aged, Neoplasm Staging, Neutropenia, chemically induced, Pilot Projects, Vinblastine, chemically induced, Feasibility Studies, Female, Cisplatin
Abstract

The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demostrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifosfamide 3 gr/sqm on day 1, Vinorelbine 25 mg/sqm on days 1,8,15, every 21 days. The dose of vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 micrograms total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63% of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52% of the courses and was given at 75% and 50% of the planned dose in 11% and 4.3% respectively; G-CSF was administered in 65.2% of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose of vinorelbine on day 15 was omitted or reduced in the majority of the cycles.

Published
1996

109. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.

Author

Ardizzoni, A., primary, Boni, L., additional, Tiseo, M., additional, Vincent, A., additional, Passalacqua, R., additional, Camerini, A., additional, Labianca, R., additional, Genestreti, G., additional, Zanelli, F., additional, Ciuffreda, L., additional, Di Costanzo, F., additional, De Marinis, F., additional, Crinò, L., additional, Santo, A., additional, Pazzola, A., additional, Barbieri, F., additional, Zilembo, N., additional, Colantonio, I., additional, Tibaldi, C., additional, and Smit, E. F., additional

Published
2011
Full Text
View/download PDF

111. Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer

Author

Baldini, E., Tibaldi, C., Chella, A., Angeletti, C. A., Romanini, A., Andrei, A., Algeri, R., Silvano, G., and PIERFRANCO CONTE

Subjects
Adult, Male, Lung Neoplasms, Carcinoma, Vinorelbine, Middle Aged, drug therapy/pathology, Vinblastine, Survival Analysis, Carcinoma, Non-Small-Cell Lung, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage/analogs /&/ derivatives, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Non-Small-Cell Lung, drug therapy/pathology, Cisplatin, administration /&/ dosage, Female, Humans, Ifosfamide, administration /&/ dosage, Lung Neoplasms, drug therapy/pathology, Male, Middle Aged, Neoplasm Staging, Survival Analysis, Vinblastine, Humans, Female, Ifosfamide, Cisplatin, administration /&/ dosage, Aged, Neoplasm Staging
Abstract

Forty-five stage IIIB-IV non-small cell lung cancer (NSCLC) patients entered a phase II study designed to evaluate the toxicity and the activity of a combination chemotherapy regimen consisting of vinorelbine (25 mg/m2 days 1 and 8), ifosfamide (3 g/m2 day 1 with uroprotective mesna), and cisplatin (80 mg/m2 day 1). The regimen, VIP, was administered on an outpatient basis every 3 weeks. White blood cell counts were checked weekly, and granulocyte colony-stimulating factor was administered in case of grade 4 neutropenia lasting for more than 48 hours. Leukopenia was the most frequent toxicity, with grades 3 and 4 neutropenia reported in 25% of cycles and 11 episodes of febrile neutropenia recorded in 175 evaluable courses. The combination of vinorelbine and cisplatin did not result in additive neurotoxicity: only five patients experienced grade 2 neurotoxicity after six courses of treatment. Thirty-five patients were evaluable for response. Twenty partial responses (57%) and one complete response (2.8%) were observed, for an overall response rate of 60% (95% confidence interval, 42% to 76%). The median time to progression, measured from the start of treatment, was 7 months (range, 1 to 18+), and median survival for the whole group was 12 months (range, 1 to 18+). VIP is a well-tolerated regimen and shows interesting activity in advanced NSCLC.

Published
1994

117. First-line chemotherapy with planned sequential administration of gemcitabine (G) followed by docetaxel (D) in elderly advanced non-small-cell lung cancer (NSCLC) patients: A multicenter phase II study

Author

Vasile, E., primary, Tibaldi, C., additional, Antonuzzo, A., additional, Di Marsico, R., additional, Tartarelli, G., additional, Fabbri, A., additional, Lo Dico, M., additional, Mazzoni, E., additional, Andreuccetti, M., additional, and Falcone, A., additional

Published
2008
Full Text
View/download PDF

118. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

Author

Tibaldi, C, primary, Vasile, E, additional, Antonuzzo, A, additional, Di Marsico, R, additional, Fabbri, A, additional, Innocenti, F, additional, Tartarelli, G, additional, Amoroso, D, additional, Andreuccetti, M, additional, Dico, M Lo, additional, and Falcone, A, additional

Published
2008
Full Text
View/download PDF

120. 1307 POSTER First-line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: a multicenter phase II study

Author

Tibaldi, C., primary, Vasile, E., additional, Lo Dico, M., additional, Antonuzzo, A., additional, Di Marsico, R., additional, Tartarelli, G., additional, Fabbri, A., additional, Mazzoni, E., additional, Andreuccetti, M., additional, and Falcone, A., additional

Published
2007
Full Text
View/download PDF

121. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

Author

D'Incecco, A, Andreozzi, M, Ludovini, V, Rossi, E, Capodanno, A, Landi, L, Tibaldi, C, Minuti, G, Salvini, J, Coppi, E, Chella, A, Fontanini, G, Filice, M E, Tornillo, L, Incensati, R M, Sani, S, Crinò, L, Terracciano, L, and Cappuzzo, F

Subjects
PROGRAMMED cell death 1 receptors, NON-small-cell lung carcinoma, PROTEIN-tyrosine kinase inhibitors, EPIDERMAL growth factor receptors, ADENOCARCINOMA
Abstract

Background:Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 are differently expressed in oncogene-addicted NSCLC.Methods:We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS mutated, 10 ALK translocated and 30 EGFR/KRAS/ALK wild type. PD-L1 and PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) in >5% of tumour cells were considered as positive.Results:PD-1 positive (+) was significantly associated with current smoking status (P=0.02) and with the presence of KRAS mutations (P=0.006), whereas PD-L1+ was significantly associated to adenocarcinoma histology (P=0.005) and with presence of EGFR mutations (P=0.001). In patients treated with EGFR tyrosine kinase inhibitors (N=95), sensitivity to gefitinib or erlotinib was higher in PD-L1+ vs PD-L1 negative in terms of the response rate (RR: P=0.01) time to progression (TTP: P<0.0001) and survival (OS: P=0.09), with no difference in PD1+ vs PD-1 negative. In the subset of 54 EGFR mutated patients, TTP was significantly longer in PD-L1+ than in PD-L1 negative (P=0.01).Conclusions:PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

122. Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients

Author

Vasile, E., primary, Giovannetti, E., additional, Tibaldi, C., additional, Mey, V., additional, Nannizzi, S., additional, Landi, L., additional, Stasi, I., additional, Danesi, R., additional, Del Tacca, M., additional, and Falcone, A., additional

Published
2006
Full Text
View/download PDF

125. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

Author

Tibaldi, C., primary, Ricci, S., additional, Russo, F., additional, Bernardini, I., additional, Galli, L., additional, Chioni, A., additional, Orlandini, C., additional, Grosso, A.M., additional, Pegna, A. Lopes, additional, Fabbri, A., additional, Innocenti, F., additional, Ferrari, K., additional, Tognarini, L., additional, Conte, P.F., additional, and Falcone, A., additional

Published
2005
Full Text
View/download PDF

134. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.

Author

Conte, P F, primary, Baldini, E, additional, Gennari, A, additional, Michelotti, A, additional, Salvadori, B, additional, Tibaldi, C, additional, Danesi, R, additional, Innocenti, F, additional, Gentile, A, additional, Dell'Anna, R, additional, Biadi, O, additional, Mariani, M, additional, and Del Tacca, M, additional

Published
1997
Full Text
View/download PDF

136. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

Author

Venturini, M, primary, Michelotti, A, additional, Del Mastro, L, additional, Gallo, L, additional, Carnino, F, additional, Garrone, O, additional, Tibaldi, C, additional, Molea, N, additional, Bellina, R C, additional, Pronzato, P, additional, Cyrus, P, additional, Vinke, J, additional, Testore, F, additional, Guelfi, M, additional, Lionetto, R, additional, Bruzzi, P, additional, Conte, P F, additional, and Rosso, R, additional

Published
1996
Full Text
View/download PDF

148. Optimization-based study of bend-twist coupled rotor blades for passive and integrated passive/active load alleviation.

Author

Bottasso, C.L., Campagnolo, F., Croce, A., and Tibaldi, C.

Subjects
COUPLINGS (Gearing), TURBOMACHINE blades, PITCH control (Aerospace engineering), MULTIDISCIPLINARY design optimization, WIND turbine blades, FLUCTUATIONS (Physics), ANGLE of attack (Aerodynamics), COMPOSITE materials testing
Abstract

ABSTRACT This work is concerned with the design of wind turbine blades with bend-twist-to-feather coupling that self-react to wind fluctuations by reducing the angle of attack, thereby inducing a load mitigation effect. This behavior is obtained here by exploiting the orthotropic properties of composite materials by rotating the fibers away from the pitch axis. The first part of this study investigates the possible configurations for achieving bend-twist coupling. At first, fully coupled blades are designed by rotating the fibers for the whole blade span, and a best compromise solution is found to limit weight increase by rotations both in the spar caps and in the skin. Next, partially coupled blades are designed where fibers are rotated only on the outboard part of the blade, this way achieving good load mitigation capabilities together with weight savings. All blades are designed with a multilevel constrained optimization procedure, on the basis of combined cross-sectional, multibody aero-servo-elastic and three-dimensional finite element models. Finally, the best configuration of the passive coupled blade is combined with an active individual pitch controller. The synergistic use of passive and active load mitigation technologies is shown to allow for significant load reductions while limiting the increase in actuator duty cycle, thanks to the opposite effects on this performance metric of the passive and active control solutions. Copyright © 2012 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

150. Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).

Author

Baldini, E, Ardizzoni, A, Prochilo, T, Cafferata, M A, Boni, L, Tibaldi, C, Neumaier, C, Conte, P F, and Rosso, R

Subjects
LUNG cancer treatment, DOSE-response relationship in biochemistry
Abstract

To evaluate activity and toxicity of a non platinum-based triplet including Gemcitabine, Ifosfamide and Navelbine (GIN) in advanced NSCLC. Stage IIIB/IV NSCLC patients with WHO PS < 2 and bidimensionally measurable disease entered the study. Gemcitabine 1000 mg/sqm day 1 and 1000-800 mg/sqm day 4, Ifosfamide 3 g/sqm day 1 (with Mesna), Navelbine 25 mg/sqm day 1 and 25-20 mg/sqm day 4 were administered intravenously every 3 weeks. Objective responses (ORs) were evaluated every 2 courses: a maximum of 6 courses were administered in responding patients. According to Simon's optimal two-stage design more than 18 ORs out of 54 patients were required to establish the activity of this regimen. Fifty patients entered the study. Main characteristics of the 48 evaluated patients were: median age 63 years, ECOG performance status 0 = 65%, stage IV disease 79% and non-squamous histology 71%. The total number of courses administered was 200, median per patient 4 (range 1-6). Toxicities were evaluated according to WHO criteria: neutropenia grade 3-4 occurred in 47% of the courses; thrombocytopenia grade 3-4 in 6.6%; anaemia grade 3 in 3.5%. Twelve episodes of febrile neutropenia were reported and three patients required hospital admission. No toxic death was reported. Non-haematological toxicity, including skin rash, alopecia and fatigue, were generally. Twenty-five ORs (1 complete response and 24 partial responses) were obtained for a response rate of 52% (95% CI: 37.4-66.5%). One-year survival was 46.5%. This non-platinum-based outpatient triplet showed promising activity against NSCLC with myelosuppression, in particular neutropenia, being dose-limiting. The GIN regimen may represent a valuable alternative to standard platinum-based doublets and triplets in the treatment of advanced NSCLC and further studies with this platinum-free combination are warranted. [ABSTRACT FROM AUTHOR]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results